[Comment] Evidence to improve the treatment of infections caused by carbapenem-resistant Gram-negative bacteria

WHO recognises carbapenem-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Entero-bacteriaceae as pathogens of crucial importance for the development of novel antibiotics.1 These bacteria manifest resistance to our most trusted therapeutics and, as a result of their increasing prevalence and transmissibility, are becoming an overwhelming health-care burden.2 Over the past decade, polymyxins (an old class of cationic antimicrobial peptide antibiotics) became the drugs of last resort to treat carbapenem-resistant Gram-negative bacteria.
Source: The Lancet Infectious Diseases - Category: Infectious Diseases Authors: Tags: Comment Source Type: research